Investment Date
May 2018
Corporate HQ
Madrid, Spain

Alcaliber is a leading independent supplier of Active Pharmaceutical Ingredient (‘API’) to the global pharmaceutical industry. Alcaliber has a 45-year track record of best-in-class industrial operations in a tightly regulated subsector niche with high barriers to entry. 

Alcaliber and its medicinal cannabis subsidiary, Linneo Health, are sector-leading businesses with state of the art production facilities and a reputation for outstanding quality of product resulting in strong, sustainable growth.

GHO value creation

Enablement & Alignment

  • Shared vision to create a dominant global leader in the space through transformational M&A
  • Uniquely placed to capitalise on the growing medicinal cannabis industry

Capability & Capacity

  • Improvement in gross margins expected with higher potency alkaloids from R&D, lean manufacturing processes and higher margins in the growing API segment
  • Investment in business development and finance functions to improve sales force effectiveness and streamline the Company
  • Investment in R&D and manufacturing footprint for maturing pipeline of anti addiction APIs

Building Strategic Footprints

  • Globally present in developed economies with significant potential in pharmerging markets
  • Numerous business development opportunities to expand across the value chain and achieve significant further scale, globally
  • Strong potential in Medicinal Cannabis segment driven by continuous de-regulation in Europe

Better, Faster + More Accessible HealthcareTM

GHO Capital invests in Sapio Sciences, a leading, high growth lab informatics platform company

Subscribe to our email alerts

Email updates